The clinical trials on this list are for breast cancer treatment. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. Does plaquenil cause sun sensitivity Does taking amoxicillin cause more plaquenil Jul 15, 2014 Along the lines of the Trial Watch series published on a monthly basis in OncoImmunology,35-38 here we summarize the dual role of autophagy in oncogenesis and tumor progression and discuss recent clinical trials investigating the use of chloroquine CQ, hydroxychloroquine HCQ in cancer patients. Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. trial applying chloroquine to conventional doxorubicin treatment of non-Hodgkins lymphoma in dogs demonstrated. The Dana-Farber/Harvard Cancer Center DF/HCC SPORE in Breast Cancer seeks to improve the understanding and treatment of breast cancer using an innovative and highly translational approach. The program consists of four projects, three cores, a developmental research program DRP and a career enhancement programs CEP. Talk to your doctor for help in deciding if one is right for you. You may want to think about taking part in a clinical trial. Chloroquine breast cancer clinical trial Chloroquine plaquil combinations - Ovarian cancer - Inspire, Time to use a dose of Chloroquine as an adjuvant to anti. Chloroquine phosphate chemical formula Chloroquine has demonstrated anti-tumor activities through autophagy inhibition and cell cycle disruption. This study aimed to assess the effect of single-agent chloroquine on breast tumor cellular proliferation in a randomized, phase II, double-blind, placebo-controlled, pre-surgical window of opportunity trial. Patients with newly diagnosed breast cancer were randomized 21 to chloroquine. A randomized, double-blind, window of opportunity trial.. Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. A trial of chemotherapy and. - Cancer Research UK. Susan G. Komen ® Breast Cancer Clinical Trial Information Helpline. If you or a loved one needs information or resources about clinical trials, call our Clinical Trial Information Helpline at 1-877 GO KOMEN 1-877- 465- 6636 or email [email protected] Abstract. The PINC trial NCT01023477 examined the dosage efficacy of oral chloroquine CQ, an autophagy inhibitor, as a neoadjuvant therapy to reduce the volume, cause regression and decrease the recurrence of breast ductal carcinoma in situ DCIS, for any grade or ER/PR/Her2 status. The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ DCIS to survive and spread. Participants will receive either chloroquine standard dose 500mg/week or chloroquine low dose 250mg/week for 1 month prior to surgical removal of the tumor.